Plné znění - 36/2019 Sb. m. s.

Sdělení o přijetí nového znění Přílohy I (Seznam zakázaných látek a metod dopingu pro rok 2018 - Mezinárodní standard)

36/2019 Sb. m. s.

Sdělení

INFORMACE

36

XXXXXXX

Xxxxxxxxxxxx xxxxxxxxxxxx věcí,

kterým xx mění x xxxxxxxx sdělení Xxxxxxxxxxxx xxxxxxxxxxxx xxxx x. 58/2007 Xx. x. x. a x. 46/2008 Sb. x. x.

Xxxxxxxxxxxx xxxxxxxxxxxx věcí xxxxxxx, xx xxx 1. xxxxx 2017 xxxx xxxxxxxxx ředitelkou XXXXXX oznámeno schválení xxxxxx xxxxx Xxxxxxx X - Xxxxxx xxxxxxxxxx xxxxx a xxxxx dopingu xxx xxx 2018 - Xxxxxxxxxxx xxxxxxxx Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx xxxxxx¹⁾.

X xxxxx xxxxxx Přílohy X xxxxxxxx souhlas Xxxxxxxxx Xxxxx republiky a xxxxxxxxx xxxxxxxxx podepsal xxxxxxx x přijetí xxxx Xxxxxxx I Xxxxxx xxxxxxxxxx.

Xxxx xxxxx Xxxxxxx X vstoupilo x xxxxxxxx x xxxxxxx s článkem 34 xxxx. 3 Úmluvy xxx 1. xxxxx 2018. Xxx Xxxxxx xxxxxxxxx vstoupilo nové xxxxx Přílohy X x xxxxxxxx dne 5. xxxxxx 2019.

Xxxx xxxxxx nového xxxxx Xxxxxxx I x xxxxxxxx xxxxxxxx xxxxxx xxxxx Xxxxxxx X xxxxxx xx 1. xxxxx 2017 a xxxxxxxxx xxx č. 80/2017 Sb. m. s.

Anglické xxxxx nového xxxxx Xxxxxxx X a xxxx překlad xx xxxxxxx xxxxxx xx xxxxxxxxx současně.

SVĚTOVÁ

ANTIDOPINGOVÁ

AGENTURA

SVĚTOVÝ XXXXXXXXXXXXX XXXXX

XXXXXX ZAKÁZANÝCH XXXXX X XXXXX DOPINGU XXX XXX 2018

MEZINÁRODNÍ XXXXXXXX

Xxxxxxxxx text Seznamu xxxx xxxxxxxxx XXXX x xxxx xxxxxxxxxx x xxxxxxxxxx x xxxxxxxxxxxxx.

X xxxxxxx xxxxxxxxxxx xxxxxxxxx xxxx xxxxxxxxx x xxxxxxxxxxxx verzí xxxx xxxxxxxxxxx anglická xxxxx.

Xxxxx Xxxxxx xxxx xxxxxx xx 1. xxxxx 2018 

XXXXXX XXXXXXXXXX XXXXX X XXXXX XXXXXXX PRO ROK 2018

XXXXXXX ANTIDOPINGOVÝ XXXXX

Xxxxxx xx 1. xxxxx 2018

XXXXX A METODY XXXXXXXX XXXXX (XXX XXXXXXX X XXXX SOUTĚŽ)

Podle xxxxxx 4.2.2 Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxx všechny Xxxxxxxx látky budou xxxxxxxxxx xx "Xxxxxxxxxx xxxxx" xxxxx xxxxx xx skupin X1, X2, X4.4, X4.5 x S6(a) x Xxxxxxxxxx metod X1, X2 x X3.

XXXXXXXX XXXXX

X0. XXXXXXXXXXX XXXXX

Xxxxxxxxx xxxxxxxxxxxxx látka, xxxxx xxxx xxxxxxxx x xxxxxxxxxxxxx xxxxxxx Seznamu x xxxx xxxxxxxx xxxxxxxxx pro xxxxxxx xxxxxxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxx xxxxxxxxxx xxxxxx (xxxx. léčiva x preklinickém xxxx xxxxxxxxx stadiu xxxxxxx xxxx xx xxxxxxxx xxxxxxxxxx, xxxxxxxxxx drogy, xxxxx xxxxxxxxx pouze xxx veterinární xxxxxxx), xx xxxxxxxx xxxxx.

X1. XXXXXXXXXX XXXXX

Xxxxxxxxxx látky xxxx zakázány.

1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (XXX):

(x) Xxxxxxxx* XXX, zahrnující:

1-androstendiol (5α-xxxxxxx-1-xx-3ß,17ß-xxxx);

1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx);

1-xxxxxxxxxxx (3α-hydroxy-5α-androst-1-en-17-on);

bolandiol (xxxx-4-xx-3ß, 17ß-diol);

bolasteron;

danazol ([1,2]oxazolo[4',5':2,3]pregna-4-en-20-yn-17α-ol);

dehydrochlormethyltestosteron (4-xxxxxx-17ß-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx);

xxxxxxxxxxxxxxxxxxxxxxx (17α-methyl-5α-androst-2-en-17ß-ol);

drostanolon;

ethylestrenol (19-xxxxxxxxx-4-xx-17α-xx);

xxxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx (17α-xxxxxx[1,2,5]xxxxxxxxxx[3',4':2,3]-5α-xxxxxxxxx-17ß-xx);

xxxxxxxxx;

4-xxxxxxxxxxxxxxxxxx (4,17ß-xxxxxxxxxxxxxxxx-4-xx-3-xx);

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx);

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx (17ß-xxxxxxx-2α,17α-xxxxxxxx-5α-xxxxxxxxx-3-xx);

xxxxxxxxxxxxxx (17ß-hydroxy-17α-methylestra-4,9-dien-3-on);

methyl-1-testosteron (17ß-xxxxxxx-17α-xxxxxx-5α-xxxxxxx-1-xx-3-xx);

xxxxxxxxxxxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx);

xxxxxXxxxxxxxxxxx;

xxxxxxxxxx (xxxxxxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxxxxxxx-4,9,11-xxxxx-3-xx);

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxx;

xxxxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxx (17ß-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxxx);

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

1-xxxxxxxxxxx (17ß-hydroxy-5α-androst-1-en-3-on);

tetrahydrogestrinon (17-xxxxxxx-18α-xxxx-19-xxx-17α-xxxxxx-4,9,11-xxxxx-3-xx);

xxxxxxxxx (17ß-xxxxxxxxxxx-4,9,11-xxxxx-3-xx);

x xxxxx látky x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx účinky.

b. Xxxxxxxxx** XXX, pokud jsou xxxxxx xxxxxxxx:

Xxxxxxxxxxxxx (5α-xxxxxxxxxxxxxxxxxx, 17ß-xxxxxxx-5α-xxxxxxxxx-3-xx);

xxxxxxxxxxxxx (xxxxxxx-5-xx-3ß,17ß-xxxx);

xxxxxxxxxxxxx (androst-4-en-3,17-dion);

boldenon;

boldion (xxxxxxxx-1,4-xxxx-3,17-xxxx);

xxxxxxxxx;

19-xxxxxxxxxxxxxxxx (estr-4-en-3,17-diol);

19-norandrostendion (estr-4-en-3,17-dion);

prasteron (xxxxxxxxxxxxxxxxxxxxx, XXXX, 3ß-hydroxyandrost-5-en-17-on);

testosteron;

a xxxxxx metabolity x xxxxxxx, xxxxxx, xxx xx x omezením xxxxx xx xx:

5α-xxxxxxxxx-3α,17α-xxxx;

5α-xxxxxxxxx-3α,17ß-xxxx;

5α-xxxxxxxxx-3ß,17α-xxxx;

5α-xxxxxxxxx-3ß,17ß-xxxx;

5ß-xxxxxxxxx-3α,17ß-xxxx;

5α-xxxxxxx-2-xx-17-xx;

xxxxxxx-4-xx-3α,17α-xxxx;

xxxxxxx-4-xx-3α,17ß-xxxx;

xxxxxxx-4-xx-3ß,17α-xxxx;

xxxxxxx-5-xx-3α,17α-xxxx;

xxxxxxx-5-xx-3α,17ß-xxxx;

xxxxxxx-5-xx-3ß,17α-xxxx;

4-xxxxxxxxxxxxx (xxxxxxx-4-xx-3ß,17ß-xxxx);

5-xxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx);

xxxxxxxxxxx;

xxx-xxxxxxxxxxxxxxxxxx;

xxxxxxxxxxxxxx;

xxxxxxxxxxxxxx;

3ß-xxxxxxx-5α-xxxxxxxxx-17-xx;

7α-xxxxxxx-XXXX;

7ß-xxxxxxx-XXXX;

7-xxxx-XXXX;

19-xxxxxxxxxxxxxx;

19-xxxxxxxxxxxxxxxxx.

2. Xxxxxxx xxxxxxxxxx xxxxx, xxxxxxxxxx:

Xxxxxxxxxxx; xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX, xxxx. xxxxxxx, XXX-4033, xxxxxxx x RAD140); xxxxxxx; xxxxxxx x xxxxxxxxxx, xxx xx x xxxxxxxx xxxxx na xx.

Xxx xxxxx xxxxxxx xxxx sekce: * "xxxxxxxx" xx xxxxxxxx x xxxxx, kterou tělo xxxxxxxx xxxxxxxxx neprodukuje. ** "xxxxxxxxx " xx xxxxxxxx k xxxxx, xxxxxx xxxx xxxxxxxx xxxxxxxxx produkuje.

S2. XXXXXXXXX XXXXXXX, XXXXXXX XXXXXXX, XXXXXXXX LÁTKY X XXXXXXXX

Xxxxxxxxxxx xxxxx a xxxxx látky x xxxxxxxx chemickou xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx xxxx xxxxxxxx:

1. Xxxxxxxxxxxxx (XXX) x xxxxxxxxxx ovlivňující erytropoézu, xxxxxx, xxx ne x omezením xxxxx xx ně:

1.1 Agonisté xxxxxxxxxxxxxxxxx xxxxxxxxx, xxxx

xxxxxxxxxxxx (xXXX); xxxxxxxxxxxxx (XXX); xxxxxxxxxx xxxxxxxx na XXX (EPO-Fc, methoxypolyethylenglykol-epoetin xxxx (XXXX)); EPO-mimetické xxxxxxxxxx x xxxxxx xxxxxxxxxx (xxxx. CNTO 530 x xxxxxxxxxxx).

1.2 Xxxxxxxxx xxxxxxxxxx hypoxii xxxxxxxxxxxxxx xxxxxxx (HIF), xxxx.

xxxxx; xxxxxx; molidustat; xxxxxxxxxx (XX-4592); xxxxx.

1.3 Xxxxxxxxxx XXXX, xxxx.

X-11706.

1.4 Xxxxxxxxxx XXX - xxxx (XXX - β), xxxx.

xxxxxxxxxxxx; xxxxxxxxxxx.

1.5 Xxxxxxxx vrozeného xxxxxxxxx xxxxxxxxx. xxxx.

xxxxxx EPO; xxxxxxxxxxxxx XXX.

2. Xxxxxxxxx xxxxxxx a xxxxxxxxx xxxxxxxxxx

2.1 Xxxxxxxxxxxxxxxxxx (XX) x luteinizační hormon (XX) x xxxxxx xxxxxxxxxx xxxxxxx, např. xxxxxxxxx, xxxxxxxxxx, gonadorelin, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx x triptorelin, u xxxx.

2.2 Xxxxxxxxxxxxxx a xxxxxx xxxxxxxxxx xxxxxxx, xxxx. kortikorelin.

2.3 Xxxxxxx xxxxxx (XX), xxxx xxxxxxxxx x uvolňující xxxxxxx, xxxxxx, xxx xx x xxxxxxxx xxxxx xx xx:

xxxxxxxxx xxxxxxxxx hormonu, xxxx. XXX-9604 x xXX 176-191; xxxxxx xxxxxxxxxx xxxxxxx xxxxxx (GHRH) x jeho xxxxxxx, xxxx. CJC-1295, sermorelin x xxxxxxxxxxx; sekretagogy xxxxxxxxx xxxxxxx (XXX), xxxx. xxxxxxx x xxxxxxxx xxxxxxxx, xxxx. xxxxxxxxxx, ipamorelin x xxxxxxxxxxx; xxxxxxxxxx xxxxxxx xxxxxxxxx xxxxxxx (XXXX), xxxx. xxxxxxxxxxxx, XXXX-1, XXXX-2 (xxxxxxxxxxx), GHRP-3, XXXX-4, XXXX-5, GHRP-6 x xxxxxxxxx.

3. Růstové xxxxxxx x xxxxxxxxxx xxxxxxxxx xxxxxxx, xxxxxx, xxx ne x xxxxxxxx pouze na xx:

xxxxxxxxxxxxx růstové faktory (XXXx);

xxxxxxxxxxxx xxxxxxx xxxxxx (XXX);

xxxxxxxx podobný růstový xxxxxx-1 (IGF-1) a xxxx xxxxxxx

xxxxxxxxxx xxxxxxx xxxxxxx (XXX);

xxxxxxx faktor xxxxxxxx x krevních xxxxxxxx (XXXX);

xxxxxxxx- β4 x xxxx xxxxxxxx, xxxx. XX-500;

xxxxxxxxxx-xxxxxxxxxxxx růstový xxxxxx (XXXX).

Xxxxx růstové xxxxxxx x modulátory xxxxxxxxx faktorů ovlivňující xxxxxxx nebo xxxxxxxxx xxxxxxxx svalů, xxxxx x xxxxxx, krevní xxxxxxxx, využití energie, xxxxxxxxxxxxx kapacitu xxxx xxxxxxxxxxx xxxx xxxxxxxxx xxxxxx.

X3. XXXX2- AGONISTÉ

Všichni xxxxxxxxxx i neselektivní xxxx-2 xxxxxxxx, včetně xxxxx xxxxxxxxx isomerů, xxxx zakázáni.

Zahrnují (xxx xx x xxxxxxxx xxxxx xx xx):

Xxxxxxxxx; xxxxxxxxxx; higenamin; xxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx.

Xxxxxxxx xxxx:

• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 1600 xxxxxxxxxx za 24 xxxxx x xxxxxxxxxx xxxxxxx, xxxxxxxxxxxxxxxx 800 xxxxxxxxxx xxxxx každých 12 xxxxx po xxxxxxxxx dávce;
• inhalační xxxxxxxxxx: xxxxxxxxx xxxxxx dávka 54 xxxxxxxxxx xx 24 hodin;
• inhalační xxxxxxxxxx: xxxxxxxxx 200 xxxxxxxxxx xx 24 xxxxx.

Xxxxxxxxxx xxxxxxxxxxx v xxxx x xxxxxxxxxxx vyšší xxx 1000 xx/xx x xxxxxxxxxx formoterolu x xxxx x xxxxxxxxxxx xxxxx xxx 40 xx/xx xxxxxx xxxxxxxxxx za xxxxxxxxx xxxxxxxxxxxx xxxxxxx, ale xxxx považována za xxxxxxxxx laboratorní xxxxx, xxxxx sportovec xxxxxxxxx xxxxxxxxxxxxx farmakokinetickou xxxxxx, xx xxxxxxxxxx výsledek xxx xxxxxxxx terapeutickou xxxxxx (x xxxxxxxx) xxxxx, než xxxx xxxxxxx xxxxxxxxx xxxxx.

X4. XXXXXXXXX X XXXXXXXXXXX XXXXXXXXXX

Xxxxxxxx xxxx xxxxxxxxxxx xxxxxxxxx x xxxxxxxxxxx xxxxxxxxxx:

1. Inhibitory xxxxxxxx, xxxxxxxxxx:

Xxxxxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxx-1,4,6-xxxxx-3-17-xxxx (xxxxxxxxxxxxxxxxx);

xxxxxxxx-3,5-xxxx-7-17-xxxx (xxxxxxxxx);

4-xxxxxxxxx-3,6,17-xxxxx (6-xxx);

xxxxxxxxx;

xxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxx, ale xx x xxxxxxxx pouze xx xx.

2. Xxxxxxxxxx xxxxxxxxxx estrogenových xxxxxxxxx (XXXX), xxxxxxxxxx:

Xxxxxxxxx;

tamoxifen;

toremifen, xxx xx s xxxxxxxx xxxxx na xx.

3. Ostatní xxxxxxxxxxxxxx xxxxx xxxxxxxxxx:

Xxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxx, ale xx x xxxxxxxx xxxxx xx xx.

4. Xxxxx xxxxxxxxxxxx xxxxxx(x) xxxxxxxxxx včetně xxxxxxxxxx xxxxxxxxxx, xxx xx x xxxxxxxx xxxxx xx ně.

5. Metaboiické xxxxxxxxxx:

5.1 Aktivátory AMP-aktivované xxxxxxxxxxxxx (AMPK), např. XXXXX; x Xxxxxxxx Xxxxxxxxx xxxxx xxxxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxxx (XXXXδ), xxxx. 2-(2-methyl-4-((4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)methylthio)phenoxy) xxxxxxxx xxxxxx (XX1516, XX501516);

5.2 xxxxxxxx a xxxxxxxx xxxxxxxx;

5.3 meldonium;

5.4 xxxxxxxxxxxx.

X5. XXXXXXXXX X MASKOVACÍ XXXXX

Xxxxxxxxxxx xxxxxxxxx a xxxxxxxxx xxxxx xxxx xxxxxxxx, stejně xxxx xxxxx xxxxx x xxxxxxxx chemickou strukturou x xxxxxxxxx xxxxxxxxxxxx xxxxxx.

Xxxxxxxx:

• Xxxxxxxxxxxx; plasmaexpandery (xxxx. xxxxxxxxxx xxxxxx xxxxxxxx, xxxxxxxx, hydroxyethylškrobu x xxxxxxxxx); xxxxxxxxxx, xxx xx x xxxxxxxx xxxxx na ně.

• Acetazolamid; xxxxxxxx; xxxxxxxxx; xxxxxxxxx; xxxxxxxxxxxx; indapamid; kanrenon; xxxxxxxx etakrynová; xxxxxxxxx; xxxxxxxxxxxxx; xxxxxxxx (xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxx, chlorothiazid); xxxxxxxxxx a xxxxxxx (xxxx. xxxxxxxxx), xxx xx x xxxxxxxx xxxxx xx xx.

X xxxxxxxx:

• xxxxxxxxxxxx; xxxxxxxxx x xxxxxx podání inhibitorů xxxxxxxxxxxxxx (např. xxxxxxxxxxx x brinzolamidu)

• Lokálního xxxxxx xxxxxxxxxxxx xxx xxxxx xxxxxxxxx

Xxxxx jakéhokoliv xxxxxxxx xxxxx se xxxxxxxxxx xxxxxxxx limitem (xx. xxxxxxxxxx, xxxxxxxxxx, xxxxx, xxxxxxx, metylefedrin x xxxxxxxxxxxxx) xx Xxxxxx Xxxxxxxxx xxxxxxxx xxxx xxxxxxxx Xxx Soutěži xx spojení x xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxxx, bude xxxxxxxxxx xx Xxxxxxxxx xxxxxxxxxxx xxxxx, xxxxx Xxxxxxxxx xxxx xxxxxxxxxx Xxxxxxxxxxxxx xxxxxxx (XX) xx tuto xxxxx xxxxx k té, xxxxx xxx xxxx xxxxxxx xx diuretikum xxxx xxxxx maskovací xxxxx.

XXXXXXXX XXXXXX

X1. XXXXXXXXXX X XXXX X XXXXXXXX XXXXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

1. Xxxxxx xxxx xxxxxxxxxxxxx xxxxxxxxxxx množství xxxxxxxxx, alogenní (xxxxxxxxx) xxxx xxxxxxxxxxx xxxx xxxx xxxxxxxxx xxxxxxx x jim podobných xxxxxxxx jakéhokoliv xxxxxx xx xxxxxxxxx systému.

2. Xxxxx xxxxxxxxx xxxxxxxx, xxxxxxx xxxx dodávky xxxxxxx.

Xxxxxxxxxx:

xxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx (xxxx. krevní náhražky xxxxxxxx xx hemoglobinu x xxxxxxxxxxxxxxxxxx xxxxxxxxxxx), xxxxxxxxxxxxxxxxxxx x xxxxxxxxxxx (XXX13), xxx xx x omezením xxxxx xx ně. Xxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxx xxxx.

3. Xxxxxxxxx forma xxxxxxxxxxxxxxx xxxxxxxxxx x xxxx xxxx x xxxxxxxx komponentami xxxxxxxxxxx xxxx xxxxxxxxxx způsoby.

M2. XXXXXXXX X FYZIKÁLNÍ XXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

1. Xxxxxxxxx, xxxx Xxxxx x Xxxxxx, za xxxxxx xxxxxxx integritu x xxxxxxxx Vzorků xxxxxxxxxx xxx Xxxxxxxxx xxxxxxxx. Xx zahrnuje xxxxxx x/xxxx xxxxxx (xxxx. xxxxxxxxxx) moči, xxx xx s xxxxxxxx xxxxx xx xx.

2. Xxxxxxxxxx infuze x/xxxx xxxxxxx více xxx xxxxxx 100 xx za 12 xxxxx xxxxx xxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxx nemocničních xxxxxxx, xxxxxxxxxxxxx zákroků nebo xxxxxxxxxx diagnostických xxxxx.

X3. XXXXXX XXXXXX

X xxxxxx xxxxxxxxxx xx xxxxxxx xxxxxxxxxxx xxxxxx je xxxxxxxx xxxxxxxxxxx:

1. Xxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxx xxxxxxx;

2. Xxxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx, vytvořených x xxxxxxxxxxx sekvencí xxxxxx x/xxxx x xxxxxxxxxxxx xxxx xxxxxxxxxxxx regulaci xxxxxx xxxxxxx.

3. Xxxxxxx xxxxxxxxxx nebo geneticky xxxxxxxxxxxxxx xxxxx;

XXXXX X XXXXXX ZAKÁZANÉ PŘI XXXXXXX

Xxxxx xxxxxxxxx X0 xx X5 x X1 až X3 xxxxxxxxx výše

jsou Xxx Xxxxxxx zakázané i xxxxxxxxxxx xxxxxxx:

XXXXXXXX LÁTKY

S6. XXXXXXXXXXX

Xxxxxxx stimulancia xxxxxx xxxxx xxxxxx případných xxxxxxxxx isomerů, xxxx. x- a X-, xxxx zakázaná.

Stimulancia zahrnují:

(a) Xxxxxxxxxxxx xxxxxxxxxxx:

Xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxx /4-fenylpiracetam (xxxxxxxx)/;

xxxxxxxxxx;

xxxxxxxxxxx;

xxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxx (x-);

xxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxxxx;

x-xxxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx.

Xxxxxxxxxxxx, xxxxx xxxx xxxxxxxx xxxxxxx x tomto xxxxxxxx, xx Xxxxxxxxxxx látkou.

(b) Xxxxxxxxxx xxxxxxxxxxx.

Xxxxxxxx (xxx xx s xxxxxxxx xxxxx xx xx):

Xxxxxxxxx (xxxxxxxxx)****;

xxxxxxxxxxx;

xxxxxxxxxxxxxxxxx;

1,3-xxxxxxxxxxxxxxxx;

xxxxxxx***;

xxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx x xxxx xxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxx);

xxxxxxxxxxxx;

xxxxx**;

xxxxxxx x xxxx analoga (např. xxxxxxxx, xxxxxxxxx x xxxx-xxxxxxxxxxxxxxxxxxxxx);

xxxxxxxxxxxxxxx;

xxxxxxxxxxxx;

xxxxxxxxxxxx***;

xxxxxxxxxxxxxxxxxxxxxxxx;

xxxxxxxxxxxx;

4-xxxxxxxxxx-2-xxxx (xxxxxxxxxxxxxx);

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxx (xxxxxxxxxxxxx);

xxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxxxx;

xxxxxxxxxxxxx*****;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx);

xxxxxxxxxxxxx

x další xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx nebo podobnými xxxxxxxxxxxx xxxxxx.

X xxxxxxxx:

• xxxxxxxxx

• xxxxxxxx xxxxxxxxx v xxxxxxx xxxxxx xxxxxxxx/xxxxxx xxxxxxx x stimulancií zahrnutých xx Xxxxxxxxxxxxxx programu xxx xxx 2018*.

* Xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxx, xxxxxxx, xxxxxxxxx x xxxxxxxx: Xxxx xxxxx jsou xxxxxxxx xx Xxxxxxxxxxxxxx programu 2018 a nejsou xxxxxxxxxx xx Xxxxxxxx xxxxx.

** Katin: je xxxxxxxx xxxxx při xxxxxxxxxxx xxxxx xxx 5 xxxxxxxxxx x 1 xx moči.

*** Xxxxxxx a xxxxxxxxxxxxx: xxxx xxxxxxxx xxx xxxxxxxxxxx vyšší xxx 10 xxxxxxxxxx v 1 ml xxxx.

**** Xxxxxxxxx (epinefrin): není xxxxxxx při lokálním xxxxxx, xxxx. xxxxx, xxxx xxxxxxxx nebo xxxx podání společně x lokálními anestetiky.

***** Xxxxxxxxxxxxx: xx xxxxxxx, xxxxx jeho xxxxxxxxxxx x moči xx xxxxx xxx 150 xxxxxxxxxx xx xxxxxxxx.

X7. XXXXXXXXX

Xxxxxxxxxxx xxxxxxxxx xxxx xxxxxxxx:

Xxxxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxx(xxxxxx);

xxxxxxxx a jeho xxxxxxxx;

xxxxxxxxxxx;

xxxxxxx;

xxxxxx;

xxxxxxxxxx;

xxxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxx.

X8. KANABINOIDY

Následující xxxxxxxxxxx xxxx zakázané:

• Přírodní xxxxxxxxxxx, xxxx. hašiš, konopí x marihuana.

• Syntetické kanabinoidy, xxxx. delta9-tetrahydrokanabinol (THC) x ostatní xxxxxxxxxxxxxx.

Xxxxx: xxxxxxxxxxxx

X9. XXXXXXXXXXXXXXX

Xxxxxxx xxxxxxxxxxxxxxx xxxxxxxx xxxxxx, xxxxxxxx, xxxxxxxxxx xxxx nitrosvalovou xxxxxxxx xxxx zakázané.

Včetně, xxx ne x xxxxxxxx pouze xx xx:

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxx.

XXXXX XXXXXXXX X&xxxx;XXXXXXXX XXXXXXXX

X1. XXXX-XXXXXXXXX

Xxxx-xxxxxxxxx jsou xxxxxxxx xxxxx v xxxxxxxxxxxxx xxxxxxxx Při Xxxxxxx, x kde xx xx xxxxxxxx x Xxxx xxxxxx.

• Xxxxxxxxxxxx xxxxx (FIA)

• Billiard (xxxxxxx xxxxxxxxxx) (XXXX)

• Xxxx (IGF)

• Lukostřelba (XX)*

• Xxxxxxxx (XXX) - xxxxx xx lyžích x akrobatické xxxxxxxx-xxxxx x X-xxxxx, x xxxxxxxxx U-rampa a "xxx air"

• Podvodní xxxxxx (xxxxxxxxx potápění) (XXXX) x xxxxxxxxxxxx xxxxxxxxxx xxxx s xxxxxxxxx xxxx bez xxxxxxx, xxxxxxxxx xxxxx x xxxxxxxxx xxxx bez xxxxxxx, xxxx immersion, xxxx blue, xxxxxxxxxxxx, xxxxxxxx xxxxx, xxxxxxx xxxxxxxx na xxxx x xxxxxxxxxx váha.

• Střelba (XXXX, IPC)*

• Šipky (XXX)

* Xxxxxxxx xxxx Xxxx xxxxxx

Xxxx-xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxx:

Xxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxx;

xxxxxxxxxx;

xxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxx;

xxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxx;

xxxxxxx;

xxxxxxx;

xxx xx s xxxxxxxx xxxxx xx xx.

Xxxxxxxxx

Xxxxxx předpis č. 36/2019 Sb. x. x. xxxxx xxxxxxxxx xxxx 26.7.2019.

Xxxxxx xxxxxxx x. 36/2019 Xx. x. x. byl xxxxxx xxxxxxx xxxxxxxxx č. 32/2023 Sb. m. s. s xxxxxxxxx xx 22.8.2023.

Xxxxx xxxxxxxxxxxx xxxxxxxx xxxxx xxxxxx xxxxxxxx xxxxxxxx x xxxxxxxx xxxx xxxxxxxxxxxxx, xxxxx se xxxx xxxxxx xxxxxxxxx xxxxx xxxxx uvedeného právního xxxxxxxx.

1) Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx xxxxxx, xxxxxxx xxx 19. října 2005 x Paříži, xxxx xxxxxxxxx x anglickém xxxxx x s xxxxxxxxx xx xxxxxxx xxxxxx pod č. 58/2007 Sb. m. s.

Nové xxxxx xxxxxxxx Úmluvy xx českého xxxxxx xxxx xxxxxxxxx pod č. 46/2008 Sb. m. s.